High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases
The DOI matches its OpenAlex record.
Abstract
PURPOSE: Samarium-153 ethylene diamine tetramethylene phosphonate ((153)Sm-EDTMP), a bone-seeking radiopharmaceutical, provides therapeutic irradiation to osteoblastic bone metastases. Because the dose-limiting toxicity of (153)Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer. PATIENTS AND METHODS: Patients with locally recurrent or metastatic osteosarcoma or skeletal metastases avid on bone scan were treated with 1, 3, 4.5, 6, 12, 19, or 30 mCi/kg of (153)Sm-EDTMP. RESULTS: Thirty patients were treated with (153)Sm-EDTMP. Transient symptoms of hypocalcemia were seen at 30 mCi/kg. Estimates of radioisotope bound to bone surfaces and marrow radiation dose were linear with injected amount of (153)Sm-EDTMP. Cytopenias also occurred in all subjects and were dose-related. At day +13 after (153)Sm-EDTMP, residual whole-body radioactivity was 1% to 65% of whole-body radioactivity considered safe for PBPC infusion, 3.6 mCi. After PBPC or marrow infusion on day +14 after (153)Sm-EDTMP, recovery of hematopoiesis was problematic in two patients at the 30 mCi/kg dose infused with less than 2 x 10(6) CD34(+)/kg on day +14, but not in other patients. Reduction or elimination of opiates for pain was seen in all patients. Patients had no adverse changes in appetite or performance status. CONCLUSION: (153)Sm-EDTMP with PBPC support can provide bone-specific therapeutic irradiation (estimates of 39 to 241 Gy). Hematologic toxicity at 30 mCi (153)Sm-EDTMP/kg requires PBPC grafts with more than 2 x 10(6) CD34(+)/kg to overcome myeloablative effects of skeletal irradiation. Nonhematologic side effects are minimal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 23
- Mausner LF, Kolsky KL, Joshi V, et al: Radionuclide development at BNL for nuclear medicine therapy. Appl Radiat Isot 4: 285,1998-294, · doi:10.1016/s0969-8043(97)00040-7
- Goeckeler WF, Troutner DE, Volkert WA, et al: 153 Sm radiotherapeutic bone agents. Nucl Med Biol 13: 479,1986-482, · doi:10.1016/0883-2897(86)90028-0
- 10.1016/0969-8043(94)90234-8 · doi:10.1016/0969-8043(94)90234-8
- 10.1200/JCO.1989.7.12.1926 · DOI
- Turner JH, Martindale AA, Sorby P: Samarium EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 15: 784,1989-795, 153 · doi:10.1007/bf00255498
- 10.3109/02841869609101655 · DOI
- 10.3109/02841869609101655 · DOI
- 10.1200/JCO.1989.7.12.1926 · DOI
- 10.1016/S0936-6555(05)81078-7 · DOI
- 10.1016/S0001-2998(05)80156-4 · doi:10.1016/s0001-2998(05)80156-4
- 10.1016/S0959-8049(97)00155-X · DOI · Paper page
- 10.1200/JCO.1998.16.4.1574 · DOI · Paper page
- 10.1007/s002590050351 · doi:10.1007/s002590050351
- 10.1016/S0167-8140(97)01912-9 · doi:10.1016/s0167-8140(97)01912-9
- 10.1016/S0969-8051(96)00117-5 · doi:10.1016/s0969-8051(96)00117-5
- Ketring AR: Sm-EDTMP and Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl Med Biol 14: 223,1987-232, 153 186 · doi:10.1016/0883-2897(87)90046-8
- Shibamoto Y, Horii N, Takahashi M: Long-term control of multiple lung metastases from osteosarcoma obtained by conventional radiotherapy: A case report. Oncol Rep 6: 1085,1999-1087, · doi:10.3892/or.6.5.1085
- 10.1097/00006231-199205000-00005 · doi:10.1097/00006231-199205000-00005
- 10.1093/jnci/85.18.1508 · doi:10.1093/jnci/85.18.1508
- Porter AT, Ben-Josef E, Davis L: Systemic administration of new therapeutic radioisotopes, including phosphorus, strontium, samarium, and rhenium. Curr Opin Oncol 5: 607,1994-610, · doi:10.1097/00001622-199411000-00013
- 10.3109/07853899708998741 · doi:10.3109/07853899708998741
- 10.1016/S0959-8049(97)00252-9 · DOI
- 10.1093/jnci/87.3.221 · doi:10.1093/jnci/87.3.221
Cited by
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 671
Primary bone osteosarcoma in the pediatric age: State of the art
Longhi, A., Errani, C., De Paolis, M., Mercuri, M., & Bacci, G. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.05.005 · Cited by 631
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
Finlay, I. G., Mason, M. D., & Shelley, M. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70206-0 · Cited by 369
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
Ozaki, T., Flege, S., Kevric, M., Lindner, N., Maas, R., Delling, G., Schwarz, R., von Hochstetter, A. R., Salzer-Kuntschik, M., Berdel, W. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.142 · Cited by 342
Radiotherapy for local control of osteosarcoma
DeLaney, T. F., Park, L., Goldberg, S. I., Hug, E. B., Liebsch, N. J., Munzenrider, J. E., & Suit, H. D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.051 · Cited by 306
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 298
Therapy for Osteosarcoma: Where Do We Go From Here?
Chou, A. J., Geller, D. S., & Gorlick, R. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00005 · Cited by 274
Liu, J., Bian, D., Zheng, Y., Chu, X., Lin, Y., Wang, M., Lin, Z., Li, M., Zhang, Y., & Guan, S. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.11.013 · Cited by 268
Osteosarcoma: Review of the Past, Impact on the Future. The American Experience
Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_12 · Cited by 252
Progress in the chemotherapeutic treatment of osteosarcoma (Review)
Zhang, Y., Yang, J., Zhao, N., Wang, C., Kamar, S., Zhou, Y., He, Z., Yang, J., Sun, B., Shi, X., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9434 · Cited by 172
“Furthermore, bone‑specific irradiation can be induced using 153 Sm-EDTMP with peripheral-blood progenitor-cell support (70).”
Hawkins, D. S., & Arndt, C. A. S. (2003) · Cancer · doi:10.1002/cncr.11799 · Cited by 147
Self-citationLewis, V. O., Ozawa, M. G., Deavers, M. T., Wang, G., Shintani, T., Arap, W., & Pasqualini, R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4845 · Cited by 79
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Gazouli, I., Kyriazoglou, A., Kotsantis, I., Anastasiou, M., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Kontogeorgakos, V., et al. (2021) · Cancers · doi:10.3390/cancers13081757 · Cited by 63
Hobbs, R. F., McNutt, T., Baechler, S., He, B., Esaias, C. E., Frey, E. C., Loeb, D. M., Wahl, R. L., Shokek, O., & Sgouros, G. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.08.022 · Cited by 53
“a variety of carcinomas is well established, and its therapeutic value for patients with osteosarcoma is being investigated (11, 12).”
BackgroundManagement of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
Pushpam, D., Garg, V., Ganguly, S., & Biswas, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s193363 · Cited by 16
“sectable bone lesions, 153Sm-EDTMP with or without stem cell support provide good pain relief.(95,96) Pushpam et al Dovepress”
BackgroundPlyku, D., Loeb, D. M., Prideaux, A. R., Baechler, S., Wahl, R. L., Sgouros, G., & Hobbs, R. F. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1803 · Cited by 10
“Although biodistribution and dosimetry studies of (153)SmEDTMP have been conducted on animals, the existing human data are almost exclusively in patients with bone metastases of epithelial cancers or for bone marrow transplant(32) or toxicity studies(33) where the focus is not on dosimetry, although with a few notable…”
Metadata
- Authors
- Anderson, P. M., Wiseman, G. A., Dispenzieri, A. A., Arndt, C. A. S., Hartmann, L. C., Smithson, W. A., Mullan, B. P., & Bruland, Ø. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-01-01
- Volume
- 20
- Issue
- 1
- Pages
- 189-196
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2116452300
- Cited by
- 214
- References
- 0
- FWCI
- 12.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.